Centocor Remicade Two-Year X-Ray Progression Data To Be Ready For Cmte.
Centocor will have two-year x-ray data on Remicade in the prevention of rheumatoid arthritis progression available for review at the upcoming meeting of FDA's Arthritis Drugs Advisory Committee.
You may also be interested in...
Immunex' Enbrel promotions may use data on percentages of patients with no increase in erosion scores and area under the curve data, but may not use the data to make superiority claims to methotrexate, the approval letter for a new indication for Enbrel states.
A planned combination trial of Hoechst Marion Roussel's Arava and methotrexate in rheumatoid arthritis may justify expanding the use of leflunomide to patients not adequately controlled by methotrexate alone, HMR consultant Marc Hochberg, MD, University of Maryland, told the Arthritis Advisory Committee Aug. 7.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011